New rationales for using TGFβ inhibitors in radiotherapy

International Journal of Radiation Biology

Volumn 83, Issue 11-12, 2007, Pages 803-811

  Andarawewa, Kumari L ^a   Paupert, Jenny ^a   Pal, Anupama ^a   Barcellos Hoff, Mary Helen ^a  

^a Life Sciences Division   (United States)

Author keywords

ATM; DNA damage; Epithelial; Tumor radiosensitivity

Indexed keywords

CISPLATIN; ENZYME INHIBITOR; MITOMYCIN C; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; ATM PROTEIN; CELL CYCLE PROTEIN; DNA BINDING PROTEIN; PROTEIN SERINE THREONINE KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN;

BREAST CANCER; CANCER INHIBITION; CANCER RADIOTHERAPY; DNA DAMAGE; DRUG INHIBITION; EPITHELIUM CELL; FIBROSIS; GENOTOXICITY; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIOBIOLOGY;

ATAXIA TELANGIECTASIA;

ANIMALS; CELL CYCLE PROTEINS; DNA DAMAGE; DNA-BINDING PROTEINS; GENE EXPRESSION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; RADIOBIOLOGY; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEINS;

EID: 36849026669     PISSN: 09553002     EISSN: 13623095     Source Type: Journal    
DOI: 10.1080/09553000701711063     Document Type: Review

References (57)

1. Ahmed MM, Alcock RA, Chendil D, Dey S, Das A, Venkatasubbarao K, Mohiuddin M, Sun L, Strodel WE, Freeman JW. 2002. Restoration of transforming growth factor-beta signaling enhances radiosensitivity by altering the Bcl-2/Bax ratio in the p53 mutant pancreatic cancer cell line MIA PaCa-2. Journal of Biological Chemistry 277:2234-2246.
2. Akhurst RJ. 2002. TGF-{beta} antagonists: Why suppress a tumor suppressor? Journal of Clinical Investigation 109:1533-1536.
3. Annes JP, Munger JS, Rifkin DB. 2003. Making sense of latent TGF{beta} activation. Journal of Cell Science 116:217-224.
4. Anscher MS, Crocker IR, Jirtle RL. 1990. Transforming growth factor b1 expression in irradiated liver. Radiation Research 122:77-85.
5. Anscher MS, Kong F, Murase T, Jirtle RL. 1995. Short communication: Normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGFb. British Journal of Radiology 68:331-333.
6. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. 1993. Transforming growth factor b as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. New England Journal of Medicine 328:1592-1598.
7. Anscher MS, Thrasher B, Rabbani Z, Teicher B, Vujaskovic Z. 2006. Antitransforming growth factor-[beta] antibody 1D11 ameliorates normal tissue damage caused by high-dose radiation. International Journal of Radiation Oncology, Biology, Physics 65:876-881.
8. Bakkenist CJ, Kastan MB. 2003. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421:499-506.
9. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM, Cornell JE, Pollock BH, Mundy GR, Sun L-Z. 2006. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-{beta} Type I receptor kinase inhibitor. Cancer Research 66:6714-6721.
10. Barcellos-Hoff MH. 1993. Radiation-induced transforming growth factor b and subsequent extracellular matrix reorganization in murine mammary gland. Cancer Research 53:3880-3886.
11. Barcellos-Hoff MH. 1994. A novel redox mechanism for TGF-beta activation. Molecular Biology of the Cell 5:139a.
12. Barcellos-Hoff MH. 1998. How do tissues respond to damage at the cellular level? The role of cytokines in irradiated tissues. Radiation Research 150:S109-120.
13. Barcellos-Hoff MH, Derynck R, Tsang ML-S, Weatherbee JA. 1994. Transforming growth factor-b activation in irradiated murine mammary gland. Journal of Clinical Investigation 93:892-899.
14. Barcellos-Hoff MH, Dix TA. 1996. Redox-mediated activation of latent transforming growth factor-b1. Molecular Endocrinology 10:1077-1083.
15. Barcellos-Hoff MH, Park C, Wright EG. 2005. Radiation and the microenvironment-tumorigenesis and therapy. Nature Review Cancer 5:867-875.
16. Brown PD, Wakefield LM, Levinson AD, Sporn MB. 1990. Physiochemical activation of recombinant latent transforming growth factor-betas 1, 2, and 3. Growth Factors 3:35-43.
17. Derynck R, Akhurst RJ, Balmain A. 2001. TGF-b signaling in tumor suppression and cancer progression. Nature Genetics 29:117-129.
18. Dubrovska A, Kanamoto T, Lomnytska M, Heldin CH, Volodko N, Souchelnytskyi S. 2005. TGFbeta1/Smad3 counteracts BRCA1-dependent repair of DNA damage. Oncogene 24:2289-2297.
19. Ehrhart EJ, Carroll A, Segarini P, Tsang ML-S, Barcellos-Hoff MH. 1997. Latent transforming growth factor-b activation in situ: Quantitative and functional evidence following low dose irradiation. Journal of the Federation of American Societies for Experimental Biology Journal 11:991-1002.
20. Erickson AC, Barcellos-Hoff MH. 2003. The not-so innocent bystander: Microenvironment as a target of cancer therapy. Expert Opinion on Therapeutic Targets 7:71-88.
21. Ewan KB, Henshall-Powell RL, Ravani SA, Pajares MJ, Arteaga CL, Warters RL, Akhurst RJ, Barcellos-Hoff MH. 2002. Transforming growth factor-b1 mediates cellular response to DNA damage in situ. Cancer Research 62:5627-5631.
22. Flanders KC, Major CD, Arabshahi A, Aburime EE, Okada MH, Fujii M, Blalock TD, Schultz GS, Sowers A, Anzano MA, Mitchell JB, Russo A, Roberts AB. 2003. Interference with transforming growth factor-{beta}/Smad3 signaling results in accelerated healing of wounds in previously irradiated skin. American Journal of Pathology 163:2247-2257.
23. Hirohashi S, Kanai Y. 2003. Cell adhesion system and human cancer morphogenesis. Cancer Science 94:575-581.
24. Jobling MF, Mott JD, Finnegan M, Erickson AC, Taylor SE, Ledbetter S, Barcellos-Hoff MH. 2006. Isoform specificity of redox-mediated TGF-b activation. Radiation Research 166:839-848.
25. Kaartinen V, Voncken JW, Shuler C, Warburton D, Bu D, Heisterkamp N, Groffen J. 1995. Abnormal lung development and cleft palate in mice lacking TGF-b3 indicates defects of epithelial-mesenchymal interaction. Nature Genetics 11:415-421.
26. Kanamoto T, Hellman U, Heldin CH, Souchelnytskyi S. 2002. Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair. Embo Journal 21:1219-1230.
27. Kirshner J, Jobling MF, Pajares MJ, Ravani SA, Glick A, Lavin M, Koslov S, Shiloh Y, Barcellos-Hoff MH. 2006. Inhibition of TGFb1 signaling attenuates ATM activity in response to genotoxic stress. Cancer Research 66:10861-10868.
28. Kong F-M, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. 1995. Elevated plasma transforming growth factor-b1 levels in breast cancer patients decrease after surgical removal of tumor. Annals of Surgery 222:155-162.
29. Kozlov S, Gueven N, Keating K, Ramsay J, Lavin MF. 2003. ATP activates Ataxia-Telangiectasia Mutated (ATM) in vitro. Importance of autophosphorylation. Journal of Biological Chemistry 278:9309-9317.
30. Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S. 1993. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proceedings of the National Academy of Sciences USA 90:770-774.
31. Lahm A, Uhl M, Lehr HA, Ihling C, Kreuz PC, Haberstroh J. 2004. Photoshop-based image analysis of canine articular cartilage after subchondral damage. Archives of Orthopaedic and Trauma Surgery 124:431-436.
32. Liu P, Menon K, Alvarez E, Lu K, Teicher BA. 2000. Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. International Journal of Oncology 16:599-610.
33. Martin M, Lefaix J, Delanian S. 2000. TGF-beta1 and radiation fibrosis: A master switch and a specific therapeutic target? International Journal of Radiation Oncology, Biology, Physics 47:277-290.
34. Miyaki M, Kuroki T. 2003. Role of Smad4 (DPC4) inactivation in human cancer. Biochemical and Biophysical Research Communications 306:799-804.
35. Moran JM, Elshaikh MA, Lawrence TS. 2005. Radiotherapy: What can be achieved by technical improvements in dose delivery? The Lancet Oncology 6:51-58.
36. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J, Easterly E, Roebuck LR, Ryan S, Gotwals PJ, Koteliansky V, Arteaga CL. 2002. Blockade of TGF-{beta} inhibits mammary tumor cell viability, migration, and metastases. Journal of Clinical Investigation 109:1551-1559.
37. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, Barcellos-Hoff MH, Moody SE, Chodosh LA, Arteaga CL. 2004. Conditional overexpression of active transforming growth factor b accelerates metastases of transgenic mammary tumors. Cancer Research 64:9002-9011.
38. Ohmori T, Yang JL, Price JO, Arteaga CL. 1998. Blockade of tumor cell transforming growth factor-betas enhances cell cycle progression and sensitizes human breast carcinoma cells to cytotoxic chemotherapy. Experimental Cell Research 245:350-359.
39. Portress DI, Bauer G, Hill MA, O'Neill P. 2007. Low-dose irradiation of nontransformed cells stimulates the selective removal of precancerous cells via intercellular induction of apoptosis. Cancer Research 67:1246-1253.
40. Pociask DA, Sime PJ, Brody AR. 2004. Asbestos-derived reactive oxygen species activate TGF-beta1. Laboratory Investigation 84:1013-1023.
41. Rabbani ZN, Anscher MS, Zhang X, Chen L, Samulski TV, Li CY, Vujaskovic Z. 2003. Soluble TGFbeta type II receptor gene therapy ameliorates acute radiation-induced pulmonary injury in rats. International Journal of Radiation Oncology, Biology, Physics 57:563-572.
42. Rifkin D. 2005. Latent Transforming Growth Factor-b (TGF-b) binding proteins: Orchestrators of TGF-b availability. Journal of Biological Chemistry 280:7409-7412.
43. Sanford LP, Ormsby I, Gittenberger-de Groot AC, Sariola H, Friedman R, Boivin GP, Cardell EL, Doetschman T. 1997. TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124:2659-2670.
44. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, Herron DK, Lampe JW, McCowan JR, McMillen WT, Mort N, Parsons S, Smith ECR, Vieth M, Weir LC, Yan L, Zhang F, Yingling JM. 2003. Synthesis and activity of New Aryl- and Heteroaryl-substituted pyrazole inhibitors of the transforming growth factor-Type I receptor kinase domain. Journal of Medicinal Chemistry 46:3953-3956.
45. Shiloh Y. 2000. ATM: Sounding the double-strand break alarm. Cold Spring Harbor Symposium on Quantitative Biology 65:527-533.
46. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. 2003. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proceedings of the National Academy of Sciences USA 100:8430-8435.
47. Stoika R, Yakymovych M, Souchelnytskyi S, Yakymovych I. 2003. Potential role of transforming growth factor beta1 in drug resistance of tumor cells. Acta Biochimica Polonica 50:497-508.
48. Suardet L, Li C, Little JB. 1996. Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. International Journal of Cancer 68:126-131.
49. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, Wakefield LM. 2003. TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. Journal of Clinical Investigation 112:1116-1124.
50. Teicher BA. 2001. Malignant cells, directors of the malignant process: Role of transforming growth factor-beta. Cancer Metastasis Reviews 20:133-143.
51. Teicher BA, Holden SA, Ara G, Chen G. 1996. Transforming growth factor-beta in in vivo resistance. Cancer Chemotherapy and Pharmacology 37:601-609.
52. Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. 1997. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: Reversal by decorin. In Vivo 11:463-472.
53. Wiegman EM, Blaese MA, Loeffler H, Coppes RP, Rodemann HP. 2007. TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiotherapy and Oncology 83:289-295.
54. Xavier S, Piek E, Fujii M, Javelaud D, Mauviel A, Flanders KC, Samuni AM, Felici A, Reiss M, Yarkoni S, Sowers A, Mitchell JB, Roberts AB, Russo A. 2004. Amelioration of radiation-induced fibrosis: Inhibition of Transforming Growth Factor-{beta} signaling by halofuginone. Journal of Biological Chemistry 279:15167-15176.
55. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, Reiss M. 2002. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: A tissue microarray study. Cancer Research 62:497-505.
56. Xu Y, Baltimore D. 1996. Dual roles of ATM in the cellular response to radiation and in cell growth control. Genes and Development 10:2401-2410.
57. Yingling JM, Blanchard KL, Sawyer JS. 2004. Development of TGF-[beta] signalling inhibitors for cancer therapy. Nature Reviews Drug Discovery 3:1011-1022.